Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal
disease. The development of safe and effective vaccines with activity across the diversity of …

Introduction The epidemiology of invasive meningococcal disease (IMD), a rare but
potentially fatal illness, is typically described as unpredictable and subject to sporadic …

Summary Background The UK introduced 4CMenB—a multicomponent vaccine against
serogroup B meningococcal disease—into the national infant immunisation programme in …

Objectives In 2015 the UK became the first country to implement the meningococcal B
(MenB) vaccine, 4CMenB, into the national infant program. 4CMenB is expected to cover …

Factor H binding protein (fHbp) is a major protective antigen in 4C-MenB (Bexsero®) and
Trumenba®, two serogroup B meningococcal vaccines, wherein expression level is a …

This study examined the capsular phenotype and genotype of invasive meningococcal
disease (IMD)-associated Neisseria meningitidis recovered in the Republic of Ireland (RoI) …

2017 年山西省婴幼儿流行性脑脊髓膜炎病例病原学分析 Page 1 *传染病监测* 2017 年山西省婴
幼儿流行性脑脊髓膜炎 病例病原学分析 韩吉婷1,杨红霞1,王洋1,杨婷婷1,张秋香1,姚素霞1,郝瑞娥 …

Meningococcal serogroup B vaccines have been licensed on the basis of safety and
immunogenicity data without efficacy studies. Establishing the breadth of coverage of these …

2017 年山西省婴幼儿流行性脑脊髓膜炎 病例病原学分析 Page 1 *传染病监测* 2017 年山西省婴
幼儿流行性脑脊髓膜炎 病例病原学分析 韩吉婷1,杨红霞1,王洋1,杨婷婷1,张秋香1,姚素霞1,郝瑞娥 …

The meningococcal serogroup B vaccine 4CMenB (Bexsero, GlaxoSmithKline) was added
to the UK routine infant immunisation programme in 2015 as a reduced dosage regimen …